Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --…
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE…
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE…
Innovative Healthcare Technology Company Recognized for Growth, Impact, and Excellence GRAND BLANC, Mich., Aug. 13, 2025 /PRNewswire/ -- Inc., the…
Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue…
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87 billion in 2024 stood at US$5.06…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with…
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4…